DySIS Cervical Cancer Screening Tool Achieves Clinical and Cost Benefits to Patients
Product News Mar 29, 2012
DySIS Medical Ltd has announced that its cervical cancer screening colposcopy technology has been assessed under an independent review for clinical and cost effectiveness and achieved outstanding results.
DySIS colposcopy uses spectral imaging to help clinicians highlight any areas of concern by mapping out the condition of a woman’s cervix.
In clinical trials, it has been shown to significantly boost sensitivity in detecting cervical cancer in its earliest stages.
Armed with this additional information, clinicians are able to take immediate steps to treat patients and prevent disease progression.
The assessment looked at the clinical and cost effectiveness of a variety of different products to improve the capability of cervical screening. It was commissioned by the NIHR HTA programme on behalf of the National Institute for Health and Clinical Excellence (NICE).
To read the report, please visit: http://www.nice.org.uk/nicemedia/live/13474/58614/58614.pdf.
The report found that DySIS colposcopy had higher sensitivity than conventional colposcopy.
The results of the economic analysis suggested that DySIS colposcopy was less costly and more effective than traditional colposcopy and that these results were robust to the numerous sensitivity analyses that were undertaken.
Cervical cancer is the second most common cancer in women and accounts for more than one in ten (9%) of diagnosed female cancers. The World Health Organization estimates that there are over 500,000 new cases each year resulting in 250,000 deaths.
In the developed world, where screening programmes are used, some 30 million women will receive an abnormal smear test result and be called for a colposcopy examination. If caught and treated at an early stage, there is a high degree of treatment success.
The introduction of cervical cancer screening in women over 25 has helped to reduce the incidence of the disease - about 4.4 million women are screened in the UK each year - even so, approximately, 900 women in England a year die of the disease and the cost to the healthcare services, including the NHS runs into multimillions.
As a result of these findings, if the DySIS product was adopted more widely in the UK, the Company believes many more women could be identified and treated for the disease earlier using much less expensive and traumatic interventions.
Alastair Atkinson, DySIS Medical CEO commented on the report, “The DySIS product is already used in hospitals and clinics throughout Europe and we’ve had a highly positive reception to initial sales in the US following our FDA clearance to market. The DySIS product is already having a major impact on women’s health in other countries and we hope to do the same in the UK.”